Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 12/20 | 1.00 |
| ▸ | PLAU | P00749 | 1/20 | 0.63 |
| ▸ | NCK1 | P16333 | 1/20 | 0.59 |
| ▸ | NCF1 | P14598 | 5/20 | 0.53 |
| ▸ | NOS2 | P35228 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL14245319 | 0.98 | BACE1 (0.96) | BACE1PLAUNCK1NCF1NOS2 | |
| SCHEMBL18317038 | 0.84 | BACE1 (1.00) | BACE1PLAUNCK1NCF1NOS2 | |
| SCHEMBL29612580 | 0.84 | BACE1 (1.00) | BACE1PLAUNCK1NCF1NOS2 | |
| SCHEMBL789486 | 0.78 | BACE1 (0.64) | BACE1PLAUKDM4EMEN1ALDH1A1 | |
| SCHEMBL3412309 | 0.77 | PLAU (1.00) | BACE1PLAUNCK1NCF1NOS2 | |
| SCHEMBL30503638 | 0.77 | PLAU (1.00) | BACE1PLAUNCK1NCF1NOS2 | |
| SCHEMBL30527824 | 0.77 | BACE1 (0.63) | BACE1KDM4EMEN1ALDH1A1MAPT | |
| SCHEMBL1914302 | 0.77 | BACE1 (0.63) | BACE1KDM4EMEN1ALDH1A1MAPT | |
| SCHEMBL7265492 | 0.77 | BACE1 (0.63) | BACE1KDM4EMEN1ALDH1A1MAPT | |
| SCHEMBL29077372 | 0.76 | BACE1 (0.61) | BACE1KDM4EMEN1ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 151 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12630529-B2 | GCN2 modulator compounds | Alesta Therapeutics BV (NL) | 2026-05-19 | — | — | US | disclosed |
| EP-4696688-A1 | BENZO-FUSED RING COMPOUND INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF | Shanghai Hansoh Biomedical Co., Ltd. (CN) | 2026-02-18 | — | — | EP | disclosed |
| EP-4680607-A1 | BICYCLIC UREAS AS KINASE INHIBITORS | Incyte Corporation (US) | 2026-01-21 | — | — | EP | disclosed |
| US-20250304582-A1 | Bicyclic Ureas As Kinase Inhibitors | INCYTE CORPORATION | 2025-10-02 | — | — | US | disclosed |
| CN-114514228-B | Pyridinamide derivatives as agricultural fungicides | 环球化学股份有限公司 | 2025-05-13 | — | — | CN | disclosed |
| WO-2024213042-A1 | BENZO-FUSED RING COMPOUND INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 上海翰森生物医药科技有限公司 | 2024-10-17 | — | — | WO | disclosed |
| US-20240317744-A1 | Bicyclic Ureas As Kinase Inhibitors | INCYTE CORPORATION | 2024-09-26 | — | — | US | disclosed |
| WO-2024191996-A1 | BICYCLIC UREAS AS KINASE INHIBITORS | INCYTE CORPORATION (US) | 2024-09-19 | — | — | WO | disclosed |
| US-20240279201-A1 | DUAL WNT SIGNALING PATHWAY INHIBITORS AND AMPK ACTIVATORS FOR TREATMENTS OF DISEASE | UNIVERSITY OF MARYLAND, BALTIMORE | 2024-08-22 | — | — | US | disclosed |
| US-20240239752-A1 | BICYCLIC HETEROAROMATIC INHIBITORS OF KLK5 | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2024-07-18 | — | — | US | disclosed |
| WO-2009039134-A1 | ANTI-INFECTIVE PYRIMIDINES AND USES THEREOF | ABBOTT LABORATORIES (US) | 2009-03-26 | — | — | WO | disclosed |
| EP-1978966-A2 | TRICYCLIC INHIBITORS OF 5-LIPOXYGENASE | Amira Pharmaceuticals, Inc. (US) | 2008-10-15 | — | — | EP | disclosed |
| EP-1836174-A2 | ARYL NITROGEN-CONTAINING BICYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS | AMGEN INC. (US) | 2007-09-26 | — | — | EP | disclosed |
| WO-2007087250-A2 | TRICYCLIC INHIBITORS OF 5-LIPOXYGENASE | AMIRA PHARMACEUTICALS, INC. (US) | 2007-08-02 | — | — | WO | disclosed |
| WO-2007087250-A2 | TRICYCLIC INHIBITORS OF 5-LIPOXYGENASE | AMIRA PHARMACEUTICALS, INC. (US) | 2007-08-02 | — | — | WO | disclosed |
| US-20070173508-A1 | TRICYCLIC INHIBITORS OF 5-LIPOXYGENASE | AMIRA PHARMACEUTICALS, INC. (US) | 2007-07-26 | — | — | US | disclosed |
| US-20070173508-A1 | TRICYCLIC INHIBITORS OF 5-LIPOXYGENASE | AMIRA PHARMACEUTICALS, INC. (US) | 2007-07-26 | — | — | US | disclosed |
| US-20070173508-A1 | TRICYCLIC INHIBITORS OF 5-LIPOXYGENASE | AMIRA PHARMACEUTICALS, INC. (US) | 2007-07-26 | — | — | US | disclosed |
| US-20070054916-A1 | Aryl nitrogen-containing bicyclic compounds and methods of use | AMGEN INC. | 2007-03-08 | — | — | US | disclosed |
| WO-2006039718-A2 | ARYL NITROGEN-CONTAINING BICYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS | AMGEN INC (US) | 2006-04-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12630529-B2 | GCN2 modulator compounds | NR3C1, GCN1, EIF2AK4 | BACE1 4366/4885PLAU 4805/4885NCK1 2110/4885 |
| US-20070173508-A1 | TRICYCLIC INHIBITORS OF 5-LIPOXYGENASE | ALOX5, ALOX15, ALOX15B | BACE1 2373/4885PLAU 855/4885NCK1 3567/4885 |
| US-20240239752-A1 | BICYCLIC HETEROAROMATIC INHIBITORS OF KLK5 | KLK5, KLK1, KLKB1 | BACE1 484/4885PLAU 982/4885NCK1 581/4885 |
| US-20250304582-A1 | Bicyclic Ureas As Kinase Inhibitors | JAK2, UCK2, ULK2 | BACE1 4877/4885PLAU 575/4885NCK1 420/4885 |
| US-20240317744-A1 | Bicyclic Ureas As Kinase Inhibitors | JAK2, UCK2, ULK2 | BACE1 4877/4885PLAU 575/4885NCK1 420/4885 |
| US-20240279201-A1 | DUAL WNT SIGNALING PATHWAY INHIBITORS AND AMPK ACTIVATORS FOR TREATMENTS OF DISEASE | PRKAB2, PRKAB1, PRKAG2 | BACE1 966/4885PLAU 1351/4885NCK1 2083/4885 |
| US-20070054916-A1 | Aryl nitrogen-containing bicyclic compounds and methods of use | MAP3K1, MAP3K5, MAP3K2 | BACE1 3036/4885PLAU 4142/4885NCK1 102/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.